State Street SPDR S&P Biotech ETF
704 hedge funds and large institutions have $6.43B invested in State Street SPDR S&P Biotech ETF in 2022 Q3 according to their latest regulatory filings, with 100 funds opening new positions, 220 increasing their positions, 225 reducing their positions, and 93 closing their positions.
4.29% more ownership
Funds ownership: 90.48% → 94.77% (+4.3%)
3% more funds holding in top 10
Funds holding in top 10: 32 → 33 (+1)
8% more first-time investments, than exits
New positions opened: 100 | Existing positions closed: 93
5% more call options, than puts
Call options by funds: $1.99B | Put options by funds: $1.9B
2% more capital invested
Capital invested by funds: $6.3B → $6.43B (+$125M)
0% less funds holding
Funds holding: 706 → 704 (-2)
2% less repeat investments, than reductions
Existing positions increased: 220 | Existing positions reduced: 225
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$154M |
| 2 |
Two Sigma Advisers
New York
|
+$112M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$84.2M |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
+$75M |
| 5 |
Two Sigma Investments
New York
|
+$55.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$143M |
| 2 |
Goldman Sachs
New York
|
-$133M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$117M |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$107M |
| 5 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$72.7M |
XBI Hedge Fund Activity: Q3 2022 in Review
704 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q3 2022, worth a combined $6.43B — up 2% from $6.3B a quarter earlier.
Buyers outnumbered sellers: 100 funds opened new XBI positions and 93 closed out — a net gain of 7 holders — while 220 added to existing stakes and 225 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $154M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $143M.
- 704 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q3 2022, down from 706 in Q2 2022.
- Funds reported $6.43B of State Street SPDR S&P Biotech ETF stock for Q3 2022, up 2% quarter-over-quarter.
- 100 funds opened new State Street SPDR S&P Biotech ETF positions in Q3 2022 and 93 closed out, a net change of +7 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q3 2022 was JP Morgan Chase, an estimated $154M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q3 2022 was BNP Paribas Financial Markets, an estimated $143M sold.
Based on aggregated 13F filings for Q3 2022.